E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial

Leukemia. 2023 Dec;37(12):2512-2516. doi: 10.1038/s41375-023-02050-4. Epub 2023 Oct 9.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Indoles
  • Neoplasms*
  • RNA Splicing
  • RNA Splicing Factors / genetics
  • Sulfonamides / therapeutic use

Substances

  • RNA Splicing Factors
  • N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzene-sulfonamide
  • Sulfonamides
  • Indoles

Associated data

  • ClinicalTrials.gov/NCT05024994